Atacicept

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Atacicept (TACI-Ig) 是一种重组融合蛋白，包含 TACI 受体的细胞外配体结合部分和人 IgG 的 Fc 部分。Atacicept 通过结合 B 淋巴细胞刺激剂和增殖诱导配体抑制 B 细胞刺激。Atacicept 可用于 B 细胞自身免疫性疾病的研究。

Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease.

——

Atacicept (TACI-Ig; 100 μg; i.p.; three times of week for 14 days; BALB/c mice) reduces mature B-cell counts and serum antibody levels in normal mice.Atacicept (TACI-Ig) inhibits the progression of disease and autoantibody titers in a mouse model of collagen-induced arthritis (CIA).Animal Model:Male DBA/1 mice with CIA modelsDosage:100 μg Administration:intraperitoneal injection; three times of week for 21 days Result:Increased serum titers of anti-collagen Abs and few overt signs of disease.Animal Model:BALB/c mice Dosage:100 μg Administration:intraperitoneal injection; three times of week for 14 days Result:Reduced mature B cell populations but had little effect on other cell lineages.Blocked the development of B cells at the transition from T1 to T2 and the development of MZ B cells in the spleen.

——

Others

Other Targets

Others

——

——

845264-92-8

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years